IDEAYA Biosciences, Inc. IDYA Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | —— | —— | —— | ||
| $339.54M+7.9% | $314.7M-14.5% | $368.29M+7.5% | $342.45M+6.1% | $322.75M+9.5% | ||
| $69.19M+9.3% | $63.32M+14.2% | $55.43M+13.6% | $48.78M+9.4% | $44.59M+13.5% | ||
| $408.74M+8.1% | $378.02M-10.8% | $423.72M+8.3% | $391.23M+6.5% | $367.35M+10.0% | ||
| $408.74M+8.1% | $378.02M-10.8% | $423.72M+8.3% | $391.23M+6.5% | $367.35M+10.0% | ||
| -$183.47M-15.2% | -$159.31M+23.7% | -$208.88M+45.6% | -$384.23M-6.6% | -$360.35M-10.2% | ||
| $43.41M-4.8% | $45.62M-5.3% | $48.14M-8.2% | $52.42M-1.6% | $53.26M+1.5% | ||
| -$140.06M-23.2% | -$113.7M+29.3% | -$160.74M+51.6% | -$331.8M-8.0% | -$307.08M-11.9% | ||
| -$1.60-22.1% | -$1.31+31.8% | -$1.92+50.1% | -$3.85-5.5% | -$3.65-8.6% | ||
| -$1.58-22.5% | -$1.29+32.1% | -$1.90+50.6% | -$3.85-5.5% | -$3.65-8.6% | ||
| 355.3M+0.1% | 355M+2.0% | 348.2M+1.0% | 344.7M+3.1% | 334.2M+4.1% | ||
| 354.2M+0.1% | 353.8M+2.0% | 347M+0.7% | 344.7M+3.1% | 334.2M+4.1% | ||
| -$142.14M-26.6% | -$112.24M+30.9% | -$162.52M+50.6% | -$328.87M-8.0% | -$304.58M-11.1% | ||
| -$2.08M-243% | $1.46M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$183.47M-15.2% | -$159.31M+23.7% | -$208.88M+45.6% | -$384.23M-6.6% | -$360.35M-10.2% | ||
| -$180.68M-15.4% | -$156.61M+24.1% | -$206.33M+46.0% | -$381.76M-6.6% | -$357.98M-10.3% | ||
| -$180.68M-15.4% | -$156.61M+24.1% | -$206.33M+46.0% | -$381.76M-6.6% | -$357.98M-10.3% | ||
| -$183.47M-15.2% | -$159.31M+23.7% | -$208.88M+45.6% | -$384.23M-6.6% | -$360.35M-10.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does IDEAYA Biosciences, Inc.'s income statement data come from?
- Every line is extracted from IDEAYA Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.